Modulating the Immune System
Home
About
Active Biotech in Brief
Board of Directors
Management
Business Concept
Corporate Governance
Corporate Governance Report 2017
Article of Association
Election Committee
General Meetings
Auditors
Partnerships
Career
Projects
Project Overview
ANYARA
Tasquinimod
SILC
Laquinimod
Paquinimod
Patents
Orphan Drug Designation
Investor
Investor
Financial Calendar
Financial Reports
Interim Reports
Annual Reports
Stock
Ownership
Official Documents
Rights Issue 2014
Rights Issue 2016
Rights Issue 2018
Media
Press Contact
Press Releases
Subscribe
News
Image Bank
Contact
Copyright © 2018 Active Biotech AB.
All Rights Reserved.
Design by
Clavis Communications
.
Media
Press Contact
Press Releases
News
Image Bank
News
Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at “European Huntington’s Disease Network (EHDN) plenary meeting 2018”
September 13, 2018
Active Biotech regains global rights to development and commercialization of laquinimod
September 5, 2018
Active Biotech AB – Interim Report January – June 2018
August 9, 2018
Active Biotech provides update on laquinimod in Huntington’s disease
July 31, 2018
The Annual General Meeting of Active Biotech was held on May 17, 2018
May 17, 2018
Annual Report 2017 Active Biotech AB (publ)
April 27, 2018
Notice of Annual General Meeting of Shareholders May 17, 2018, at 5 pm
April 18, 2018
Active Biotech’s rights issue over subscribed
April 16, 2018
Active Biotech’s partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer
April 12, 2018
Prospectus relating to Active Biotech’s rights issue published
March 27, 2018
This site uses cookies.
Okay, thanks
